AChE was targeted by several drug discovery campaigns, resulting in the approval of four drugs for the treatment of AD (donepezil, rivastigmine, galantamine, tacrine), as AChE inhibitors (AChEIs) [55]. The gene discussed is ACHE; the disease is Alzheimer disease.